Contract research organization

WCCT Global opens a newly Asian bridging clinical trials unit

Posted on Updated on

WCCT Global, a full service contract research organisation (CRO), has opened a new Asian Bridging clinical research site. This state of the art facility has been reconfigured to provide for 30 semi-private rooms to give each clinical trial volunteer a more comfortable experience for extended in-house stays.

This dedicated clinical pharmacology unit is located in Orange County, California which is a central location enabling access to the many Asian populations that reside in the surrounding communities. WCCT Global has been conducting Asian bridging clinical trials for over 10 years and has conducted the largest Asian bridging clinical trial ever done in the United States.

Over the past 5 years WCCT Global has conducted over 60 Asian Bridging studies and recruited over 1600 Asian volunteers during this 3-year period.  Interestingly, over 20 per cent of those trials have required extended overnight confinement (> 4 days) to the research centre.

Therefore, the availability of this “built-to-suit” extended stay facility will provide a more comfortable and attractive setting for research participants. WCCT Global reports that based upon volunteer exit survey results, safety and comfort are the two most important determinants for a volunteer’s decision to participate in ‘extended stay’ clinical trials. Therefore, WCCT Global has also designed this new facility to accommodate every aspect of a volunteer’s research experience, from the meals they are provided to the utilisation of their free-time in order to make the volunteers stay as enriched, safe and comfortable as possible.

WCCT Global’s chief operating officer, Jon Rojas, stated “We decided to reconfigure this research centre in response to our study participants’ survey responses.  I think that we have created an extended-stay research centre that will provide the safe and comfortable environment that our Asian bridging study volunteers have expressed the desire for. We wanted a unit that can make our volunteers as comfortable as possible while offering our clients the best ethno-bridging solution available.”

Source: PharmaBiz

This entry was posted in Clinical Research, Clinical Trial and tagged , , , , , , .

GVK BIO to acquire Aragen Bioscience, Inc.

Posted on Updated on

Asia’s leading small-molecule contract research organization (CRO), GVK BIO and Aragen Bioscience, Inc., a privately held US based, pre-clinical CRO specializing in high-value biologics services, have entered into an agreement to acquire the capital stock of Aragen Bioscience. GVK BIO has established itself as a pre-eminent small molecule service provider. This is GVK BIO’s first international acquisition; the financial details were not disclosed.

This deal enables GVK BIO to expand its service offering to a broader base of organizations and gives GVK BIO expertise in biologics services and a significant US presence. The acquisition provides Aragen with the ability to expand its service offerings, access to GVK BIO’s global sales force and access to new markets.

The acquisition of Aragen Bioscience provides GVK BIO with world-class expertise in large molecule R&D services and a unique and extensive set of high-content biological services. Combined with GVK BIO’s established small molecule discovery and development capabilities, this expansion uniquely position GVK BIO as a leading provider of integrated R&D services across both large and small molecule platforms and provides a base for further expansion.

D S Brar, chairman, GVK BIO, said,“As an increasing number of biotech and pharmaceutical companies focus on protein based therapeutics and biosimilars, the acquisition of Aragen Bioscience will strategically enhance GVK BIO’s ability to offer high quality R&D services to the industry from a seamless integrated platform.”

“Aragen’s scientific excellence and expertise in large-molecule R&D services combined with GVK BIO’s scale, resources, and global reach will create significant synergies for both companies” stated Rick Srigley, president & CEO, Aragen Bioscience.

GVK BIO provides a broad spectrum of integrated services, across the R&D and manufacturing value chain with a focus on speed and quality. GVK BIO capabilities include discovery research, discovery services, clinical development, contract manufacturing, formulations and informatics. GVK BIO’s 2400 employees serve a diverse and global customer base of more than 300 satisfied customers.

Aragen Bioscience, Inc. is a privately held contract research organization with offices and laboratories in the San Francisco Bay Area. Aragen Bioscience offers a diverse set of services for the discovery, characterization, activity assessment and early development of biologic and diagnostic products.

Source : PharmaBiz

Related articles

 

This entry was posted in Clinical Trial, Research and development and tagged , , .

D A Prasanna elected ACRO India’s new chairman

Posted on Updated on

The Association of Contract Research Organizations (ACRO) India has unanimously elected D A Prasanna, founder and chairman Ecron Acunova, as the chairman of the Association. He took over from Apurva Shah, group managing director, Veeda Clinical Research Pvt. Ltd.

Speaking on the appointment, D A Prasanna said that clinical research in India has contributed to bringing vaccines, drugs, devices to needy patients at affordable prices. From neglected diseases like kala azar to tropical disease like malaria, Indian clinical research has alleviated suffering. India has made a name in the world in lowering healthcare costs through generics and building a reputation in development of biotech drugs and medical devices. In the last few years, clinical research has come under criticism as being unsafe and severe regulation has been imposed.

ACRO India’s priority is to promote safe conduct of clinical research without impeding the development of much needed drugs for Indian patients. ACRO India will promote global best practice to make Indian research data useful to market drugs developed in India, across the world.

As the founder and chairman of Ecron Acunova CRO, Prasanna has built an Indian CRO with presence in 28 countries and helped bring advanced cell therapy drugs to generic drugs to Indian and global patients. He has experience in leveraging Asian competitiveness, building successful global business in medical technology for GE and software for Wipro. Considered a thought leader in Life Sciences, he has held global CEO positions in GE Healthcare and was vice chairman of Wipro. He serves on biotechnology vision group of Karnataka government.

ACRO India founded and registered in India in 2005 has been formed under the aegis of Confederation of Indian Industry (CII) for bringing all CROs operating in India under one common platform. ACRO India will promote quality research, uphold ethics, share best practices, promote synergies amongst members, to deliberate and act upon common concerns, specially with regard to Indian regulations and industry environment. ACRO India will represent the interests of Indian CROs to regional, national and international authorities and organizations.

Source:PharmaBiz

This entry was posted in Clinical Trial and tagged , , .

Aurous HealthCare- CRO 5th Anniversary!

Posted on Updated on

5th_birthdayAurous HealthCare turned 5 this September and we couldn’t be more proud!!!

Apart from the celebrations at our Corporate Office, this year’s anniversary was marked with a significant event of Launching our Quarterly      Newsletter – AurouSpeak!AurouSpeak

AurouSpeak comes to you every quarter  with the latest information from the world of drug research and clinical trials in particular.

We would like to personally share a copy of the first edition of AurouSpeak with you..

(Click the link below to download. To subscribe, send a email to mgr.bd@auroushealthcare.com or corporate@auroushealthcare.com

AurouSpeak-Sep13-Aurous HealthCare CRO Newsletter

This entry was posted in Aurous HealthCare, AurouSpeak and tagged , , , , .